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lary committee members. METHOD: We addressed the
issue in two steps: First, we developed guiding principles
which should be evidence based, applicable, and credible,
and second, we proposed a method called randomized
clinical trial (RCT)—matched-arm comparison to estab-
lish therapeutic equivalence where the application of the
appropriate statistical tests, as well as the a priori defini-
tion of the clinical meaningfulness of the results is
stressed. RESULTS: The guiding principles stress the fol-
lowing domains with respect to study selection: The liter-
ature search, the definition and comparison of the popu-
lation parameters such as the pathologic condition,
inclusion and exclusion criteria, baseline characteristics,
placebo response, the drugs, the outcome, and issues such
as drug safety, potential of drug-drug interactions and
potential compliance issues. Once appropriate RCTs have
been identified and comparability is established, the pri-
mary endpoints of the two treatment arms of the two
RCTs are compared through statistical equivalence tests
using a priori defined meaningful differences for clinical end-
points. CONCLUSION: The application of the principles
and the RCT-matched-arm comparison should lead deci-
sion-makers to applicable valid decisions based on unbi-
ased results, with accurate, reproducible comparisons
and predictable clinical results.
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OBJECTIVE: Many pivotal clinical trials include an eco-
nomic component. Because of cost and logistic con-
straints, trials are rarely conducted in every nation where
the product will be marketed. For that reason economic
results obtained in one nation (“source”) are often pre-
sented to decision-makers in another nation (“target”).
Information may be seen as more relevant if findings
from the source nation are projected to the target nation.
Study objective was to identify sources of cross-national
variation in the cost of an episode of care, approaches to
adjust variation, and practical problems in trans-national
adaptation of economic clinical trials. RESULTS: We
present a case study based on analysis of economic end-
points from the Donepezil Nordic Family Impact Study.
Through literature review and experience, we identified
four potential components of transnational cost varia-
tion: 1) relative prices for services (i.e. primary care office
visit fee relative to price for chest X-ray), 2) quantity of
resources (i.e. length of stay for similar hospital admis-
sion), 3) inputs to health production (certain procedures/
services are performed in one nation but do not exist in
the other), and 4) patient population (case definition and
patient demographic characteristics). Approaches to ad-
dressing each source of variation include 1) substituting
unit prices of the target country, 2) adjusting observed re-
source quantity to typical treatment pattern of the target
country, 3) replacing selected treatment encounters with
functionally analogous service existing in target country,
and 4) sub-setting original trial cohort to obtain outcomes
in a patient population representative of the target country.
CONCLUSIONS: Adapting a pharmacoeconomic study is
a process of modifying empirical data. The sequence of ad-
justments represents a progressive trade-off between inter-
nal validity (reliance on empirical data) and external validity
(replication of the target country environment). Transpar-
ency enhances credibility of this process by demonstrating
the separate effect of each category of adjustment.
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OBJECTIVE: There are three main aims of this study. (1)
To create a profile of the state of health in the Danish
population.For this purpose we selected three multi-attrib-
ute classification systems: EQ-5D, SF-36 and 15D. The
selection of instruments was based, inter allia, on the
availability of validated Danish versions and on the in-
struments being used internationally. (2) To evaluate the
instruments in terms of their validity and reliability in
measuring a population’s health status. (3) To compare
the instruments in the measurement and evaluation of
health-related quality of life. METHODS: The study is
based on postal questionnaires, performed by a profes-
sional survey institute. A random sample of around 6.000
individuals of the Danish adult population was contacted
by phone, asking whether they would be interested in
completing the questionnaires. Around 5.000 agreed to
participate, and 3.400 responded (a response rate of
68%). The questionnaires contained all three instruments,
including the complete EQ-5D VAS scaling exercise. A
randomized experiment with 6 versions of EQ-5D con-
taining varied wording and response categories was also
embedded in the study. CONCLUSION: This study will
provide a rich data set, the analysis of which should be
an important contribution to the measurement and valu-
ation of health-related quality of life both in Denmark
and in the wider international context. 
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OBJECTIVE: Evaluate earnings associated with early,
late, or any stages of ARM, a progressive vision-compro-
mising condition, compared to a general elderly cohort.
METHODS: Earnings of an ARM population 65 years
and a general cohort 65 years were retrospectively eval-
uated to estimate potential earnings differences. ARM
prevalence data were obtained from prospective land-
mark studies in the US, Australia, and The Netherlands.
Prevalence data and census data, were used to estimate
the number of ARM patients in these countries. Beaver
Dam (BD) study income data were used to calculate the
median income for each stage of ARM. US Social Secu-
rity (SS) median income data for the general cohort pop-
ulation 65 was calculated using identical BD income
categories. BD income was adjusted for inflation and re-
gional differences. By multiplying the estimated number
of patients per given country within each specified earn-
ings category of ARM by respective median incomes, an-
nual societal earnings were calculated. Likewise, multi-
plying the number of elderly without ARM by the SS
median annual income produced an income estimate of
persons without ARM. RESULTS: Estimated BD in-
comes for persons with ARM 65 years were $27,000,
$21,000 and $27,000 for the early, late, and any groups,
respectively. The income for the general population 65
was estimated at $31,000. The early ARM group has
higher earnings related to the higher prevalence of this
cohort, and possibly higher per capita income in what is
likely to be a younger sub-population. Total estimated
earnings for the any ARM group were $240 billion. By
comparison, the total income for “no” ARM was $803
billion. ARM patients are 26% of the 65 years popula-
tion but earn only 23% of this group’s income. This pat-
tern was repeated across five studies. CONCLUSION:
The wage impact associated with ARM appears large and
represents a significant indirect societal cost of AMD.
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OBJECTIVE: To define actual practice patterns for glau-
coma and estimate the resources utilization, total cost of
treatment and costs distribution in patients categorised
into groups according to type of glaucoma and then
stratified according to stage of illness. METHODS: The
observational study included 193 patients with open-angle
(OAG) and 122 patients with closed-angle glaucoma
(CAG) recruited by ophthalmologist in Mazowian Re-
gional Centre of Glaucoma Diagnosis and Treatment. Pa-
tients were categorised into OAG and CAG groups and
then stratified according to intraocular pressure (16
mmHg-I, 17–22 mmHg-II, 22 mmHg-III) or changes in
C/D (C/D0,5-a, C/D0,6-b). Number of eyes in exam-
ined subgroups were: OAG I-154, II-165, III-45, 1–124,
2–240; CAG I-113, II-74, III-40, 1–114, 2–113, respec-
tively. The perspective of health-care payers and time ho-
rizon 18 months were taken. Quantities of resources or
services used and their costs were collected separately,
and then quantities multiplied by the price. Costs were
summarized for the main resource categories (pharma-
ceuticals, outpatient consultations, surgery, laser ther-
apy). Resources used and costs in each group were calcu-
lated per 100eyes/1year, what permitted a cross-group
comparison. RESULTS: The total cost of glaucoma treat-
ment was highest in CAG-III (108032 PLN/100eyes/1year,
1 USD  4,5 PLN) and OAG-III or b (99400 PLN/
100eyes/1year). The major cost driver in CAG-a and
OAG-b was surgery (36% of total costs), in all other,
mostly in stage III, were pharmaceuticals: in OAG-III and
CAG-III–50%, in OAG-b – 40% of total costs. In OAG-2
and CAG-b, CAG-I and CAG-II 30% of total costs arose
from surgery. The most frequent used pharmaceuticals
were: in OAG–timolol, in CAG–pilocarpine. The third–
dorzolamid-was used in OAG nad CAG, most frequent
in stage III. CONCLUSION: The total cost of glaucoma
treatment and costs distribution depends on the severity
of illness. Beyond CAG-a and OAG-b group, the most
expensive was pharmacological treatment.
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OBJECTIVE: To compare costs and effects of continuous
terbinafine and intermittent itraconazole in the treatment of
toenail onychomycosis in Poland. This was intended to
facilitate the decision-making process in selecting the more
cost-effective treatment for toenail onychomycosis. METH-
ODS: L.I.O.N. study results were used to estimate effec-
tiveness of terbinafine 0,25 g/d for 12 or 16 weeks (T12,
T16) and itraconazole 0,4 g/d for 1 week in every 4 weeks
for 12 or 16 weeks (I3, I4). The measure of treatment ef-
fectiveness was complete cure and average number of dis-
ease-free days per patient. Direct medical costs were esti-
mated on the basis of current treatment patterns in Poland.
The perspective of health care payers and time horizon of
72 weeks were taken. The decision model was used to
quantify cost and effectiveness of alternative treatments.
One-way, two-way sensitivity analysis and treshold anal-
ysis were performed. RESULTS: Cost/patient cured and
cost/disease-free day were (in PLN, 1 USD  4,5 PLN)):
for T12 - 2199 and 10,6 for T16 - 2279 and 10,6, for I3 -
4207 and 16,9, for I4 - 4670 and 20,3. Incremental anal-
ysis suggests, that I3 and I4 are dominated programs,
